Updated: AbbVie leaves some oncology programs out of 2023 pipeline highlights
2023-02-09
临床1期临床3期临床2期上市批准临床终止
In an investor update Thursday morning, AbbVie left eight programs out of its pipeline highlights it shared with investors, as compared to what exists on the R&D page of its website, last refreshed in December.
A Phase III study of Rinvoq
in Takayasu arteritis
, a rare group of disorders in which blood vessels become inflamed, was not included. The JAK inhibitorJAK inhibitor is approved for indications like rheumatoid arthritis and carries with it a black box warning.
There’s also the removal of late-stage veliparib in breast and ovarian cancers after multiple
failures
for the PARP inhibitorPARP inhibitor were
announced years ago
.
A company spokesperson noted the programs remain ongoing.
“The updates listed in the slide from this morning highlight our key programs of interest for the investment community and is not a comprehensive snapshot of our entire pipeline,” the spokesperson wrote in an email.
Further down the pipeline, AbbVie was quiet on Phase II assets ABBV-4083 in filarial diseases and its Allergan-snagged AGN-231868 in dry eye. A different Allergan asset continues in dry eye, according to the Chicago-area pharma giant’s
pipeline update
Thursday.
Down in Phase I, AbbVie left out four oncology drug candidates. The company reneged on solid and hematologic tumor assets
ABBV-155
and
ABBV-621
, an IV-infused drug candidate also known as
eftozanermin alfa
. Small cell lung cancer asset
ABBV-011
no longer shows up on the pipeline, and the same goes for
ABBV-368
in solid tumors. AbbVie previously nixed a Phase Ib study of ABBV-368 in combination with Idera’s (Aceragen as of last month) tilsotolimod.
In its update, AbbVie reminded investors of its four regulatory submissions: Rinvoq for Crohn’s disease; the Genmab-partnered
CD3xCD20 bispecific
epcoritamab
for relapsed/refractory diffuse large B-cell lymphoma; ABBV-951 for
advanced Parkinson’s disease
and Qulipta
for chronic migraine prevention
.
Editor’s note: This article has been updated to include comment and additional context from an AbbVie spokesperson that the programs remain ongoing.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。